Nos tutelles

CNRS

LabEx

Rechercher



Accueil > Membres et visiteurs > Les membres > Annuaire

Perrier Lionel

publié le , mis à jour le

CV

Manager of the area "Innovations and Strategies"

Ph.D. in Economics, Accreditation to supervise doctoral research (HDR)

Cancer Centre Léon Bérard
Clinical Research and Innovation Direction (DRCI)
GATE Lyon Saint-Etienne - UMR CNRS 5824

lionel.perrier@lyon.unicancer.fr

Main research topics

  • Health technology assessment (cost-effectiveness analyses)
  • Financing of care

Main current research projects (since 2012 with grant supports)

  • Economic impact of Next-generation sequencing (NGS) technologies (French National Cancer Institute (INCa), AAP NGS, 2014-2015)
  • Health economics evaluation of percutaneous vertebroplasty compared to radiation therapy in patients with painful spine metastases (French National Cancer Institute (INCa), AAP PRME-K, 2013-2015)
  • Health information system evaluation (Ministry of Health (DGOS), AAP PREPS, 2013-2017)
  • Economic evaluation of a second opinion in sarcoma, GIST, and desmoid tumour treatments (French National Cancer Institute, 2012-2013)

Latest Publications (since 2012)

  • Perrier L., Buja A., Mastrangelo G., Sylvestre Baron P., Ducimetière F., Pauwels P., Rossi CR., Gilly FN., Martin A, Favier B., Farsi F, Laramas M., Baldo V., Collard O., Cellier D., Blay JY., Ray-Coquard I. (2014) Transferability of health cost evaluation across locations in oncology : cluster and principal component analysis as an explorative tool. BMC Health Serv Res.. Nov 18 ;14(1):537
  • Havet N., Penot A., Morelle M., Perrier L., Fervers B. (2014) Inégalités d’exposition aux agents cancérogènes, mutagènes ou reprotoxiques (CMR) en milieu professionnel en France. Environnement, Risque, Santé. 13 (8)4 : 336-341
  • Cox DG., Ragusa S., Pourtau L., Perrier L., Delaloge S. (2014) Cost-effectiveness of a Genetic Test for Breast Cancer Risk – Letter. Cancer Prev Res (Phila). Feb 5
  • Silva ML., Perrier L., Späth HM., Grog I., Mosnier A., Havet N., Cohen JM. (2014). Economic burden of seasonal influenza B in France during winter 2010-2011. BMC Public Health. 14(1):56
  • Touillaud M., Foucaut AM., Berthouze SE., Reynes E., Kempf-Lépine AS., Carretier J., Pérol D., Guillemaut S., Chabaud S., Bourne-Branchu V., Perrier L., Trédan O., Fervers B., Bachmann P. (2013). Design of a randomised controlled trial of adapted physical activity during adjuvant treatment for localised breast cancer : the PASAPAS feasibility study. BMJ Open. 28(10) : e003855
  • Pommier P, Morelle M, Millet-Lagarde F, Peiffert D, Gomez F, Perrier L. (2013). Curiethérapie : valorisation et aspects médico-économiques. Cancer Radiother.. 17(2):178-81
  • Perrier L., Lefranc A., Pérol D., Quittet P., Schmidt-Tanguy A., Siani C., de Peretti C., Favier B., Biron P., Moreau P., Bay JO., Lissandre S. Jardin F., Espinouse D., Sebban C. (2013). Cost-effectiveness of pegfilgrastim versus filgrastim after high dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma : An economic evaluation of the PALM trial. Appl Health Econ Health Policy. 11 (2):129–138
  • Perrier L., Morelle M., Pommier P., Lagrange JL., Laplanche A., Dudouet P., Mahé M., Chauvet B., Nguyen TD., Créhange G., Beckendorf V., Pene F., Muracciole X., Bachaud JM., de Crevoisier R. (2013). Cost of prostate Image-Guided Radiation Therapy : results from a randomized trial. Radiother Oncol.. 106 (1) :50-58
  • Silva ML., Moumjid N., Perrier L., Späth HM. (2012). The use of economic evaluations in health decision making at the macro level : a literature review. Journal de gestion et d’économie médicales 30 (4) : 231-251
  • Pommier P., Morelle M., Perrier L., de Crevoisier R., Laplanche A., Dudouet P., Mahé MA., Chauvet B., Nguyen TD., Créhange G., Zawadi A., Chapet O., Latorzeff I., Bossi A., Beckendorf V., Touboul E., Muracciole X., Bachaud JM., Supiot S., Lagrange JL.(2012). Evaluation économique prospective de la radiothérapie guidée par l’image des cancers de la prostate dans le cadre du programme national de Soutien aux Thérapeutiques Innovantes et Coûteuses. Cancer Radiother. 16(5-6):444-51
  • Perrier L., Buja A., Mastrangelo G., Vecchiato A., Sandona P., Ducimetiere F., Blay J.Y., Gilly F.N., Siani C., Biron P., Ranchere-Vince D., Decouvelaere A.V., Thiesse P., Bergeron C., Dei Tos A.P., Coindre J.M., Rossi C.R., Ray-Coquard I.(2012). Clinicians’ adherence versus non adherence to practice guidelines in the management of patients with sarcoma : a cost-effectiveness assessment in two European regions. BMC Health Serv Res. Mar 28 ;12(1):82
  • Sebban C., Lefranc A., Perrier L., Moreau P, Espinouse D, Schmidt A, Kammoun L, Ghesquieres H, Ferlay C, Bay JO, Lissandre S, Pérol D, Michallet M, Quittet P. (2012). A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). Eur J Cancer. 48(5):713-20

Teaching activities

  • Evaluation of health care programmes and Health economics, Master of sciences, Lumiere Lyon 2 University
  • Cost-effectiveness analysis : methodology, applications, and perspective in environmental interventions, Master of sciences, Ecole Centrale Lyon, France

Contact

Address : Centre Régional de Lutte Contre le Cancer Léon Bérard, Direction de la Recherche Clinique et de l’Innovation (DRCI), 28 rue Laënnec 69008 Lyon, France

Phone :+33(4) 78.78.29.08 / 27.52

Fax :+33(4) 78.78.59.45